BNET Industries
Market Cap:$172.9M
Last Fiscal Year Sales:$66.1M
- Public
- US
Dow Jones Description
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. With fewer than 40 employees, POZEN is focused in the pain area of innovative drug development and in creating strategic, high-value partnerships with larger pharmaceutical companies for the commercialization of the company's drug candidates.
President, CEO and Chairman
John R. PlachetkaNumber of Employees 34
Contact Information
1414 Raleigh Rd Ste 400
Chapel Hill, North Carolina 27517-8834
(919) 913-1030
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pozen hits on profit, misses on revenue
-
POZEN Reports Third Quarter 2009 Results
-
Pozen looks to focus on commercialization [The Herald-Sun, Durham, N.C.]
-
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
-
POZEN Announces July 28, 2009 Webcast of Second Quarter 2009 Results
-
Uphill battle for migraine drug
News & Analysis
Filter by
biotechnology and pozen inc. - All News and Analysis
POZEN To Present at the 3rd Annual Citi Biotech Day
CHAPEL HILL, N.C. -- POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 1:50 p.m. ET in New York City. POZEN is a pharmaceutical...
POZEN To Present at the Seventh Annual Needham & Co., LLC Biotechnology & Medical Technology Conference
CHAPEL HILL, N.C. -- POZEN Inc. (NASDAQ: POZN) announced today that William L. Hodges, the company's chief financial officer, will present at The Seventh Annual Needham & Co., LLC Biotechnology & Medical Technology Conference on Thursday, June 12, 2008 at 1:30 p.m. ET at the New York Palace Hotel. ...
POZEN to Present at the Needham Sixth Annual Biotechnology & Medical Technology Conference
CHAPEL HILL, N.C. -- POZEN Inc. (NASDAQ: POZN) announced today that William L. Hodges, the company's chief financial officer, will present at the Needham Biotechnology & Medical Technology Conference on Thursday, June 14, 2007 at 1:00 p.m. ET at the New York Palace Hotel in New York City. POZEN...
Chapel Hill, N.C.-Based Biotech Firm Files Papers for Public Offering.(Knight Ridder/Tribune Business News)
Aug. 15--CHAPEL HILL, N.C.--Pozen Inc., which hopes to become the third Triangle-based biotechnology company to go public this year, has set its sights on attaining a market value in the neighborhood of $400 million. In its latest filing with the Securities and Exchange Commission,...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| John G. Fort | Chief Medical Officer |
| William L. Hodges | Senior Vice President Finance & Administration and Chief Financial Officer |
| Everadus Orlemans | Senior Vice President, Product Development |
| Gilda M. Thomas | Senior Vice President |
| James Alexander | senior vice president, product |
| Kristina M Adomonis | Senior Vice President, Business Development |
| John E. Barnhardt | Vice President, Finance and Administration and Principal Accounting Officer |
| Fran Barsky | Director, Ir |
| Helga L Leftwich | Secretary |
| Kenneth B. Lee Jr. | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| John R. Plachetka | President, CEO and Chairman |
| Arthur S. Kirsch | Chairman |
| Bruce A. Tomason | Chairman |
| Jacques F. Rejeange | Chairman |
| James J. Mauzey | Board of Directors |
| Joseph Mauzey James | Board of Directors |
| Paul J. Rizzo | Board of Directors |
| Peter J. Wise | Co-Founder, Director and Vice Chairman of the Board of Directors |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | President, CEO and Chairman | Current |
| POZEN, Inc. | Founder | Current |
| The University of Arizona | Assistant Professor of Pharmacy Practice | Former |
| University of Missouri-Kansas City | doctor of pharmacy degree | Former |
| University of Missouri-Kansas City | Degree | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Chief Medical Officer | Current |
| Pharmacia Corporation | Vice President, Arthritis and Pain | Former |
| Adolor Corporation | Vice President, Medical Affairs | Former |
| Thomas Jefferson University | Associate Prof of Medicine | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Senior Vice President Finance & Administration and Chief Financial Officer | Current |
| The Crosland Group Inc. | Managing Director | Current |
| POZEN, Inc. | Board of Directors | Current |
| Pergo AB | chief financial officer | Former |
| Pergo AB | senior vice president | Former |
| Banc of America Securities LLC | head of Debt Capital Markets | Former |
| Burroughs Wellcome Co. - USA | Former | |
| Georgia State University | master's degree in finance | Former |
| The University of North Carolina at Chapel Hill | Bachelor's Degree In Business Administration, Accounting | Former |
| The University of North Carolina at Chapel Hill | Batchelor's Degree in Business Administration, Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Senior Vice President, Product Development | Current |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Senior Vice President | Current |
| EMD Lexigen Research Center Corp. | General Counsel & Vice President | Current |
| POZEN, Inc. | General Counsel | Current |
| POZEN, Inc. | Board of Directors | Current |
| Emd Pharmaceuticals, Inc. | Vice President | Former |
| Emd Pharmaceuticals, Inc. | General Counsel | Former |
| Burroughs Wellcome Co. - USA | Former | |
| Emd Pharmaceuticals, Inc. | Board of Directors | Former |
| Harvard Law School | Juris Doctor Degree | Former |
| Simmons College | Masters' Degree | Former |
| Wellesley College | Bachelor's Degree | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | senior vice president, product | Current |
| The University of Mississippi | M.D. | Former |
| University of Mississippi | M.D. | Former |
| The University of Alabama at Birmingham | M.P.H. | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Senior Vice President, Business Development | Current |
| Over-The-Counter.Com | Vice President of Global Business Development and Licensing | Former |
| McGill University | MBA | Former |
| Tufts University | Bachelor's Degree In Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Vice President, Finance and Administration and Principal Accounting Officer | Current |
| POZEN, Inc. | Board of Directors | Current |
| Medco Research, Inc. | chief financial officer | Former |
| North Carolina State University | Bachelor's Degree In Zoology | Former |
| North Carolina State University | Batchelor's Degree in Zoology | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Director, Ir | Current |
Arthur Kirsch is a Managing Director with Savvian, focusing on the Healthcare sector. He has 31 years of investment banking / capital markets experience, in a broad range of capacities. Prior to Savvian, Arthur was a Managing Director at Vector Securities and held senior management positions at Natwest Securities, and Drexel Burnham Lambert. He received his BS from the University of Rhode Island and his MBA from Baruch College.
| Organization | Position | Status |
|---|---|---|
| Savvian LLC | Managing Director | Current |
| Vector Securities | Managing Director | Current |
| POZEN, Inc. | Chairman | Current |
| Vector Corporation | Former | |
| POZEN, Inc. | Board of Directors | Former |
| Baruch College | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Alterna | Chief Executive Officer | Current |
| POZEN, Inc. | Chairman | Current |
| One Call Medical, Inc. | Chief Executive Officer | Former |
| One Call Medical, Inc. | President | Former |
| Evans Medical Inc. | Vice President | Former |
| The Corporate Development Company | Manager | Former |
| POZEN, Inc. | Board of Directors | Current |
Mr. Jacques Rejeange joined the board of directors of POZEN in February of 2007 and is a member of the nominating/corporate governance committee. Mr. Rejeange was previously appointed to the POZEN Board of Directors in April 1997 and served as Chairman of the Board of Directors from December 1999 to December 2000 before his retirement in 2004. He currently sits on the Boards of Medicentrix AG and Swisslog AG in Switzerland. Previously, Mr. Rejeange was President of Florham Consulting S.A. based in Areuse, Switzerland; Chief Operating Officer and later President and Chief Executive Officer of Sterling Winthrop, Inc.; and President and Chief Executive Officer of Sandoz Pharmaceuticals Corporation USA.
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Chairman | Current |
| POZEN, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Secretary | Current |
Mr. James J. Mauzey joined the board of directors in May 2006 and is the chairman of the compensation committee. Mr. Mauzey has over 30 years experience in the pharmaceutical industry. He was formerly president and chief executive officer of Bertek Pharmaceuticals, Inc, a division of Mylan Laboratories, Inc. Prior to that, he was chief executive officer of Innovex Worldwide, the contract sales division of Quintiles Transnational Organization and chairman and chief executive officer of Alteon Inc. In addition, Mr. Mauzey has held numerous sales, marketing and executive positions with Lederle Laboratories and Bristol-Myers Squibb Company. Mr. Mauzey received a bachelor's degree from Lewis University and an MBA from Xavier University.
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Board of Directors | Current |
| Bertek Pharmaceuticals Inc | Chief Executive Officer | Former |
| Bertek Pharmaceuticals Inc | President | Former |
| Lederle Laboratories | Former | |
| Bristol-Myers Squibb Company | Former | |
| Xavier University | MBA | Former |
| Lewis University | Bachelor's Degree | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Board of Directors | Current |
Ken is co-founder of Hatteras Venture Partners II and former co-head of the International Life Science Practice at Ernst & Young; He is currently Chairman of Inspire Pharmaceuticals, and a member of the boards of OSI Pharmaceuticals, CV Therapeutics and Pozen.
| Organization | Position | Status |
|---|---|---|
| Hatteras Venture Partners | Co-Founder | Current |
| N.C. Bioscience | General Partner, Hatteras Biocapital, Llc | Current |
| Ranexa | General Partner of Hatteras Biocapital | Current |
| Hatteras Biocapital, LLC | General Partner | Current |
| Lifeheart.Com | General Partner of Hatteras Biocapital | Current |
| OSI Pharmaceuticals, Inc. | Certified Public Accountant | Current |
| Inspire Pharmaceuticals, Inc. | Chair of Board | Current |
| OSI Pharmaceuticals, Inc. | Board of Directors | Current |
| Ranexa | Director | Current |
| POZEN, Inc. | Director | Current |
| Amgen Fremont | Board of Directors | Current |
| CV Therapeutics Inc. | Board of Directors | Current |
| Lifeheart.Com | Director | Current |
| N.C. Bioscience | Board of Directors | Current |
| Hatteras Biocapital, LLC | Managing Member | Current |
| A. M. Pappas & Associates | President | Former |
| Hatteras Venture Partners | General Partner | Former |
| Ernst & Young | partner | Former |
| Young Corporation | Director of The Life Science Practice | Former |
| The University of North Carolina at Chapel Hill | MBA | Former |
| Lenoir-Rhyne College | Bachelor of Arts Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Franklin Street Partners | Partner | Current |
| Oberlin Capital, L.P. | Principal | Current |
| Geomagic, Inc. | Current | |
| Franklin Street Partners | Chairman | Current |
| Aris Partners LLC | Chairman of Franklin Street Partners | Current |
| Cox Enterprises, Inc. | Board of Directors | Current |
| Maersk Inc. | Board of Directors | Current |
| POZEN, Inc. | Board of Directors | Current |
| International Business Machines Corporation | Vice Chairman | Former |
| Johnson & Johnson | Director | Former |
| Morgan Stanley | Director | Former |
| McGraw Hill | Director | Former |
| The University of North Carolina at Chapel Hill | Bachelor's Degree In Commerce | Former |
| Organization | Position | Status |
|---|---|---|
| POZEN, Inc. | Co-Founder, Director and Vice Chairman of the Board of Directors | Current |
| POZEN, Inc. | Board of Directors | Current |
| Pharmaceutical Product Development, Inc. | President | Former |
| Pharmaceutical Product Development, Inc. | Chief Operating Officer | Former |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes


